Allogene Therapeutics, Inc. Operating Leases, Rent Expense
Allogene Therapeutics, Inc. (ALLO) reported Operating Leases, Rent Expense of $3.96 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2021-02-25
- Allogene Therapeutics, Inc. operating leases, rent expense for the quarter ending 2020-06-30 was $342.00K, a 25.27% increase year-over-year.
- Allogene Therapeutics, Inc. operating leases, rent expense for the quarter ending 2020-03-31 was $718.00K, a 43.69% decline year-over-year.
- Allogene Therapeutics, Inc. operating leases, rent expense for the quarter ending 2019-12-31 was $1.95M, a 66.95% increase year-over-year.
- Allogene Therapeutics, Inc. operating leases, rent expense for the quarter ending 2019-09-30 was $3.28M, a 393.83% increase year-over-year.
- Allogene Therapeutics, Inc. operating leases, rent expense for fiscal 2020 was $3.96M, a 41.64% decline from fiscal 2019.
- Allogene Therapeutics, Inc. operating leases, rent expense for fiscal 2019 was $6.78M, a 269.92% increase from fiscal 2018.
- Allogene Therapeutics, Inc. operating leases, rent expense for fiscal 2018 was $1.83M.
| Period end | Operating Leases, Rent Expense 1 month | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | $3.96M 10-K · filed 2021-02-25 | ||||
| 2020-06-30 | $342.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.06M 10-Q · filed 2020-08-05 | $3.01M derived: sum of 3 quarters · filed 2021-02-25 | $6.29M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-03-31 | $718.00K 10-Q · filed 2020-05-06 | $2.67M derived: sum of 2 quarters · filed 2021-02-25 | $5.95M derived: sum of 3 quarters · filed 2021-02-25 | $6.22M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $5.23M derived: sum of 2 quarters · filed 2021-02-25 | $5.50M derived: sum of 3 quarters · filed 2021-02-25 | $6.78M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $3.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $3.55M derived: sum of 2 quarters · filed 2020-08-05 | $4.83M 10-Q · filed 2019-11-05 | $6.00M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $273.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.55M 10-Q · filed 2020-08-05 | $2.72M derived: sum of 3 quarters · filed 2021-02-25 | $3.38M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $1.27M 10-Q · filed 2020-05-06 | $2.44M derived: sum of 2 quarters · filed 2021-02-25 | $3.11M derived: sum of 3 quarters · filed 2021-02-25 | $3.11M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.83M derived: sum of 2 quarters · filed 2021-02-25 | $1.83M derived: sum of 3 quarters · filed 2021-02-25 | $1.83M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $664.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $664.00K derived: sum of 2 quarters · filed 2019-11-05 | $664.00K 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $0.00 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |